LJPC has been recommended by the nº1 ranked US biotech analyst, Steve Delco, working at Fortis. I have read his research and I am convinced there is great value at current prices below 6. I saw the arithmetics on the board, mines are a little bit different. Using a 20% discount rate and discounting CF 9 years from now, I think NPV of CF between now and 2010 is over 100 per share. To this add a residual PE multiple of 30x and you get to 700$ in 9 years , i.e. 116 bagger or a performance of 69% CAGR.
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Rat